T-Cell Mediated Rejection After Belatacept Conversion in Kidney Transplant Patients
Author Information
Author(s): Bertrand Dominique, Chavarot Nathalie, Olagne Jérôme, Greze Clarisse, Gatault Philippe, Danthu Clément, Colosio Charlotte, Jaureguy Maïté, Duveau Agnès, Bouvier Nicolas, Le Meur Yannick, Golbin Léonard, Thervet Eric, Thierry Antoine, François Arnaud, Laurent Charlotte, Lemoine Mathilde, Anglicheau Dany, Guerrot Dominique
Primary Institution: Rouen University Hospital, Rouen, France
Hypothesis
What is the incidence of acute rejection after conversion to belatacept in kidney transplant recipients?
Conclusion
The study found a low incidence of T-cell mediated rejection (5.2%) after conversion to belatacept, with significant factors influencing graft survival.
Supporting Evidence
- The incidence of TCMR was 5.2% and ABMR was 0.9%.
- Death-censored graft survival was 70.1%, 55.1%, and 50.8% at 1, 3, and 5 years post-rejection.
- Shorter time between kidney transplantation and conversion was associated with TCMR occurrence.
- Patients with TCMR had a significant decrease in eGFR at the time of rejection.
Takeaway
This study looked at kidney transplant patients who switched to a new medicine called belatacept and found that not many had problems with their new medicine.
Methodology
A retrospective multicenter study analyzing 901 kidney transplant recipients who converted to belatacept from 2011 to 2021.
Potential Biases
Potential bias due to the retrospective design and the exclusion of certain patient groups.
Limitations
The retrospective nature of the study may introduce bias, and the study did not include patients who received belatacept as de novo therapy.
Participant Demographics
Patients included were kidney transplant recipients from 13 French centers, with a median age of 56.9 years.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website